GU Cancers 2022 | Urothelial carcinoma trial data presented at ASCO GU 2022

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on trial data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022. This included data presented on trastuzumab, sacituzumab govitecan and pembrolizumab in patients with urothelial carcinoma (UC) who are platinum refractory, as well as data on trastuzumab, nivolumab and deruxtecan. Dr Rosenburg emphasizes immunotherapy as a treatment to watch for in the future, and to expect to see numerous trials exploring HER2-directed antibody drug conjugates (ADCs), including RC48 that appears to demonstrate high antitumor activity for patients with advanced UC expressing HER2. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.